In vivo selection of gene modified hepatocytes
基因修饰肝细胞的体内选择
基本信息
- 批准号:10623157
- 负责人:
- 金额:$ 49.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AcetaminophenAdultAnimalsCell TherapyCell TransplantationCellsClinicalCytochrome P450DNA Sequence AlterationDNA cassetteDataDiseaseDisease modelDoseDoxycyclineEnvironmentEnzymesEventFeverFutureGene ModifiedGene TargetingGene TransferGenesGeneticGrowthGuide RNAHepatocyteHepatotoxicityHumanInjuryKnock-outLaboratoriesLentivirus VectorLiverLiver diseasesMediatingMedicineMessenger RNAMetabolic DiseasesMethodologyMethodsMicroRNAsMusNADPH-Ferrihemoprotein ReductaseParentsPharmaceutical PreparationsPopulationProliferatingReactionReagentRecombinant adeno-associated virus (rAAV)ResistanceSystemTechnologyTestingTherapeuticTransplantationWorkclinical applicationcofactordesignefficacy studygene correctiongene repairgene therapyhomologous recombinationimprovedin vivoknock-downknockout geneliver injurymanufacturenanoparticlenonhuman primatenovelpre-clinicalsafety studysmall hairpin RNAsmall moleculetherapeutic transgenetransduction efficiencyvector
项目摘要
Today the clinical application of many otherwise promising new strategies for liver directed gene and cell
therapy is hampered by their inherent quantitative inefficiency. Here we propose to use in vivo selection to
overcome these problems. We will develop clinically applicable ways to use small molecule drugs to select
genetically modified hepatocytes in vivo and thereby cross the quantitative threshold required for permanent
therapeutic benefit. We have identified the fever medication acetaminophen (APAP) as excellent candidate for
this approach.
Three specific aims are designed to fully validate these novel method for in vivo selection of therapeutically
modified hepatocytes.
In Aim 1, we will develop integrating rAAV vectors (Generide vectors) that can be selected by APAP and in aim
2,conditionally selectable lentiviral vectors will be generated. Both will be validated in metabolic disease
models. In Aim 3, we will apply the results of Aims 1&2 to human hepatocytes. Selection of genetically
modified human hepatocytes will be carried out in liver chimeric mice.
目前,许多有前途的肝定向基因和细胞治疗新策略的临床应用,
治疗受到其固有的定量低效的阻碍。在这里,我们建议使用体内选择,
克服了这些问题。我们将开发临床适用的方法,使用小分子药物来选择
基因修饰的肝细胞,从而越过永久性免疫所需的定量阈值。
治疗益处。我们已经确定了发热药物对乙酰氨基酚(APAP)作为
这种方法。
设计了三个具体目的以充分验证这些用于体内选择治疗性药物的新方法。
修饰肝细胞。
在目标1中,我们将开发整合rAAV载体(Generide载体),其可以通过APAP和目标中选择
2,将产生条件选择性慢病毒载体。两者都将在代谢性疾病中得到验证
模型在目标3中,我们将目标1和2的结果应用于人肝细胞。遗传选择
修饰的人肝细胞将在肝嵌合小鼠中进行。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Complete correction of murine phenylketonuria by selection-enhanced hepatocyte transplantation.
通过选择增强肝细胞移植完全纠正小鼠苯丙酮尿症。
- DOI:10.1101/2023.08.27.554228
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Vonada,Anne;Wakefield,Leslie;Martinez,Michael;Harding,CaryO;Grompe,Markus;Tiyaboonchai,Amita
- 通讯作者:Tiyaboonchai,Amita
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Markus Grompe其他文献
Markus Grompe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Markus Grompe', 18)}}的其他基金
In vivo targeting of diabetes-relevant human cell types with rAAV vectors
rAAV 载体体内靶向糖尿病相关人类细胞类型
- 批准号:
8812513 - 财政年份:2014
- 资助金额:
$ 49.51万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 49.51万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 49.51万 - 项目类别:
Grant-in-Aid for Scientific Research (C)